Open access
60
Views
13
CrossRef citations to date
0
Altmetric
Original Research
Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis
Claus Vogelmeier1 Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, Member of the German Center for Lung Research (DZL), Marburg, GermanyCorrespondence[email protected]
, Nanshan Zhong2 State Key Laboratory, Guangzhou Institute of Respiratory Diseases, First Affiliated Hospital, Guangzhou Medical University, Guangzhou
, Michael J Humphries3 Beijing Novartis Pharma Co. Ltd., Shanghai, People’s Republic of China
, Karen Mezzi4 Novartis Pharma AG, Basel, Switzerland
, Robert Fogel5 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
, Giovanni Bader4 Novartis Pharma AG, Basel, Switzerland
, Francesco Patalano4 Novartis Pharma AG, Basel, Switzerland
& Donald Banerji5 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
show all
Pages 3189-3197
|
Published online: 14 Dec 2016
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.